On November 9, 2017 Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported that it will report its financial results for the third quarter ended September 30, 2017 on Monday November 13, 2017 after market close (Press release, ProMetic Life Sciences, NOV 9, 2017, View Source [SID1234521898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prometic will host a conference call at 11:00am (ET) on Tuesday November 14, 2017. The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. A live audio webcast of the conference call will be available via: View Source;s=1&k=99570B881A8129DE3DCA8DE3EBD93544

An audio replay of the call will be available as of Tuesday November 14, 2017 at 2:00pm (ET). The numbers to access the audio replay are 416-849-0833 and 1-855-859-2056 using the following password (3866799).

On November 9, 2017 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported that the Company will participate in the following upcoming investment conferences (Press release, Inovio, NOV 9, 2017, View Source [SID1234521873]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2017 Healthcare Conference
Presentation and 1×1 meetings
Dr. Niranjan Y. Sardesai, COO
11:45 AM ET, November 15, 2017
New York, NY

29th Annual Piper Jaffray Healthcare Conference
Presentation and 1×1 meetings
Dr. J. Joseph Kim, President & CEO
9:00 AM ET, November 29, 2017
New York, NY

Citi’s 2017 Global Healthcare Conference
1×1 meetings only
Dr. J. Joseph Kim, President & CEO
December 6-7, 2017
New York, NY

The live and archived version of the Piper Jaffray presentation will be available on Inovio’s website at View Source

On November 9, 2017 LIDDS reported that it has entered a research collaboration with the Department of Laboratory Medicine at Karolinska Institute, Sweden (Press release, Lidds, NOV 9, 2017, View Source [SID1234555923]). The collaboration regards fundamental preclinical studies on formulations based on the NanoZolid technology, as well as access to risk laboratories for formulation development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LIDDS broadens its R&D activities to develop novel NanoZolid formulations for local tumor therapy by establishing a collaboration with Professor Mustapha Hassan and Dr. Ying Zhau at the Department of Laboratory Medicine (LABMED) at Karolinska Institute in Huddinge.

– LIDDS appreciate very much the collaboration with KI, and I am confident that the ongoing collaborative research will be fruitful and supportive to develop new efficient formulations with the NanoZolid technology. We are also pleased with the preclinical expertise that we have encountered at the Department Laboratory Medicine at Novum, states CEO of LIDDS Monica Wallter.
The collaboration includes fundamental preclinical studies and gives access to risk laboratories for formulation development with hazardous substances. Within the frame of the collaboration, novel NanoZolid formulations will be investigated prior to entering the clinical phase.

OncoGenex Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, OncoGenex Pharmaceuticals, 2017, NOV 9, 2017, View Source [SID1234521846]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Propanc has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Propanc, 2017, NOV 9, 2017, View Source [SID1234521912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!